Vlada Injac has a strong background in regulatory affairs, with extensive experience in the pharmaceutical industry. They started their career at Hemofarm in 2004, initially working in the marketing department as a Marketing Specialist. In this role, they were responsible for analyzing the pharmaceutical market and making suggestions for introducing new products. They also created New Product Files, which included pharmacoepidemiology, pharmacoeconomy, and sales predictions.
In 2006, Vlada transitioned to the Regulatory Affairs Department at Hemofarm, where they served as a Project Leader. They were involved in pre- and post-marketing authorization regulatory activities and played a key role in preparing documentation for CTD Modules 1, 2, 4, and 5. Their responsibilities included drafting SmPC, PIL, labels, and Non-clinical and Clinical Overviews.
In 2017, Vlada joined Accelsiors CRO as a Regulatory Affairs Manager II. They quickly progressed to the role of Regulatory Affairs Director, where they continued to demonstrate their expertise in regulatory affairs. Currently, Vlada holds the position of VP Regulatory Affairs at Accelsiors CRO.
Overall, Vlada Injac has a strong background in regulatory affairs, particularly within the pharmaceutical industry, with significant experience in documentation preparation and project leadership.
Vlada Injac completed their Doctor of Medicine (MD) degree at the Medical School, University of Novi Sad from 1997 to 2003. They then pursued a Master of Science (MSc) in Pharmacology at the Medical School, University of Belgrade from 2007 to 2008. Following this, they obtained an MSc in Pharmaceutical Medicine from the same institution in 2008. In 2009, Vlada Injac specialized in Clinical Pharmacology at the Medical School, University of Belgrade and earned the title of specialist. In 2014, they began their Doctor of Philosophy (PhD) in clinical pharmacology at the Medical School in Kragujevac, Serbia, which they completed in 2017. Finally, Vlada Injac pursued a second Doctor of Philosophy (PhD) in Clinical Pharmacology at both the Medical School University of Kragujevac, Serbia, and the Medical School University of Belgrade. No specific start and end years are provided for these two PhD programs.
October, 2022 - present
July, 2017
May, 2017
VP, Regulatory Affairs at Genprex
VP, Regulatory Affairs & Quality at ALX Oncology
VP, Regulatory Affairs at ClearPoint Neuro
VP, Regulatory Affairs & Quality Assurance at ivWatch
VP, Regulatory Affairs & Quality Assurance at OrphoMed
Access the worlds's biggest network of public org charts
Learn more